Zhejiang Medicine (600216.SH): Plans to invest 60 million yuan to participate in the establishment of Zhuji PuHua Zhuoran Venture Capital Partnership.

Gelonghui, May 15th ─ Zhejiang Pharmaceutical (600216.SH) announced that on May 15, 2026, the company signed the 'Partnership Agreement of Zhuji Puhua Zhuoran Venture Capital Partnership (Limited Partnership)' with the general partner Hangzhou Puhua Tianji Equity Investment Management Co., Ltd., limited partners Jinggong (Shanghai) Investment Management Co., Ltd., and Zhuji Puzhen Taichen Venture Capital Partnership (Limited Partnership). They will jointly invest in Zhuji Puhua Zhuoran Venture Capital Partnership (Limited Partnership). The total subscribed capital contribution of the partnership is RMB 151 million, with the company acting as a limited partner contributing RMB 60 million from its own funds.

Gelonghui FinanceMay 15 15:59

Zhejiang Medicine: First Quarter Report for 2026

SZSIApr 24 00:00 · Announcements

Zhejiang Pharmaceutical First Quarter 2026 Report

SZSIApr 24 00:00 · Announcements

Zhejiang Pharmaceutical (600216): Company performance under short-term pressure in 2025; Vitamin prices rebound in 1Q26; Innovative drug R&D pipeline continues to advance.

Event: On April 10, 2026, Zhejiang Pharmaceutical released its annual report for 2025. The company’s operating revenue in 2025 was RMB 8.881 billion, a year-on-year decrease of 5.28%; net profit attributable to shareholders was RMB 873 million.

Great Wall SecuritiesApr 23 19:37

Zhejiang Medicine Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Simply Wall StApr 15 06:51

Zhejiang Medicine to Spin Off Subsidiary for Hong Kong Listing; Shares Down 4%

MT NewswiresApr 13 11:02